The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
WJOG13219G: Triplet versus doublet in patients with previously untreated BRAFV600E-mutant metastatic colorectal cancer: A multi-institutional real-world data analysis (BRACELET study).
 
Keitaro Shimozaki
No Relationships to Disclose
 
Kenro Hirata
No Relationships to Disclose
 
Tarou Sato
No Relationships to Disclose
 
Maho Nakamura
No Relationships to Disclose
 
Kyoko Kato
No Relationships to Disclose
 
Hidekazu Hirano
No Relationships to Disclose
 
Yosuke Kumekawa
No Relationships to Disclose
 
Kaori Hino
No Relationships to Disclose
 
Kentaro Kawakami
No Relationships to Disclose
 
Yosuke Kito
Honoraria - Chugai Pharma; Merck; Taiho Pharmaceutical; Takeda
 
Toshihiko Matsumoto
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
 
Takeshi Kawakami
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Masato Komoda
Honoraria - Eisai; Lilly Japan
 
Kengo Nagashima
Consulting or Advisory Role - Fujimoto; Senju Pharmaceutical; Toray Industries
Speakers' Bureau - Pfizer
 
Yasunori Sato
Speakers' Bureau - Eisai; Kowa Pharmaceutical; Mochida Pharmaceutical Co. Ltd.
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Shuichi Hironaka
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Nihonkayaku; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Tsumura & Co.; Yakult Honsha
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toyama Chemical Co (Inst); Yakult Honsha (Inst)
 
Yasuo Hamamoto
Research Funding - Ono Pharmaceutical
 
Hiromasa Takaishi
No Relationships to Disclose
 
Kei Muro
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen Astellas BioPharma; Astellas Pharma; Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Mediscience Planning (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Solasia Pharma (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical